Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR2 | Q8TDS4 | 3/20 | 0.81 |
| ▸ | MAPK10 | P53779 | 3/20 | 0.76 |
| ▸ | TSHR | P16473 | 2/20 | 0.76 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.76 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.76 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.74 |
| ▸ | MEN1 | O00255 | 2/20 | 0.74 |
| ▸ | CASP3 | P42574 | 1/20 | 0.74 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.74 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.74 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.74 |
| ▸ | NPC1 | O15118 | 5/20 | 0.68 |
| ▸ | RAB9A | P51151 | 4/20 | 0.68 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.66 |
| ▸ | POLB | P06746 | 2/20 | 0.66 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.66 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.65 |
| ▸ | EPAS1 | Q99814 | 1/20 | 0.65 |
| ▸ | TP53 | P04637 | 1/20 | 0.59 |
| ▸ | RECQL | P46063 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8943790 | 0.98 | HCAR2 (0.79) | HCAR2MAPK10TSHRALDH1A1HSD17B10 | |
| SCHEMBL5696427 | 0.91 | HCAR2 (0.78) | HCAR2MAPK10TSHRALDH1A1HSD17B10 | |
| SCHEMBL4912964 | 0.90 | NPC1 (0.80) | HCAR2MAPK10TSHRALDH1A1HSD17B10 | |
| SCHEMBL18510324 | 0.90 | NPC1 (0.80) | HCAR2MAPK10TSHRALDH1A1HSD17B10 | |
| SCHEMBL4914608 | 0.90 | HCAR2 (0.76) | HCAR2MAPK10TSHRALDH1A1HSD17B10 | |
| SCHEMBL4915695 | 0.90 | HCAR2 (0.76) | HCAR2MAPK10TSHRALDH1A1HSD17B10 | |
| SCHEMBL8689332 | 0.90 | HCAR2 (1.00) | HCAR2MAPK10TSHRALDH1A1HSD17B10 | |
| SCHEMBL14449495 | 0.89 | HCAR2 (0.77) | HCAR2MAPK10TSHRALDH1A1HSD17B10 | |
| SCHEMBL11597574 | 0.88 | MAPK10 (0.72) | HCAR2MAPK10TSHRALDH1A1HSD17B10 | |
| SCHEMBL5696407 | 0.87 | HCAR2 (0.76) | HCAR2MAPK10TSHRALDH1A1HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-7179411-A | — | — | None | — | — | JP | disclosed |
| US-11691983-B2 | Specifically substituted benzofuro- and benzothienoquinolines for organic light emitting diodes | IDEMITSU KOSAN CO., LTD. (JP) | 2023-07-04 | — | — | US | disclosed |
| US-11691983-B2 | Specifically substituted benzofuro- and benzothienoquinolines for organic light emitting diodes | IDEMITSU KOSAN CO., LTD. (JP) | 2023-07-04 | — | — | US | disclosed |
| US-20190161497-A1 | SPECIFICALLY SUBSTITUTED BENZOFURO- AND BENZOTHIENOQUINOLINES FOR ORGANIC LIGHT EMITTING DIODES | IDEMITSU KOSAN CO., LTD. (JP) | 2019-05-30 | — | — | US | disclosed |
| WO-2011057110-A1 | GPR109A AGONISTS FOR THE TREATMENT OF CEREBRAL ISCHEMIA | RUPRECHT-KARLS-UNIVERSITAT-HEIDELBERG (DE) | 2011-05-12 | — | — | WO | disclosed |
| US-20110065676-A1 | COMBINATION THERAPIES COMPRISING PAR1 ANTAGONISTS WITH NAR AGONISTS | SCHERING CORPORATION (US) | 2011-03-17 | — | — | US | disclosed |
| EP-1656139-A1 | ARYL DICARBOXAMIDES | Applied Research Systems ARS Holding N.V. (AN) | 2006-05-17 | — | — | EP | disclosed |
| WO-2005011685-A1 | ARYL DICARBOXAMIDES | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (NL) | 2005-02-10 | — | — | WO | disclosed |
| US-5925647-A | TREATMENT OF INSULIN NON-INSULIN DEPENDENT DIABETES | SHAMAN PHARMACEUTICALS, INC. (US) | 1999-07-20 | — | — | US | disclosed |
| US-5741926-A | ANTIDIABETIC AGENT | SHAMAN PHARMACEUTICALS, INC. (US) | 1998-04-21 | — | — | US | disclosed |
| US-5681958-A | TREATMENT OF DIABETES | SHAMAN PHARMACEUTICALS, INC. (US) | 1997-10-28 | — | — | US | disclosed |
| WO-1997030019-A1 | ANILINE DERIVATIVES HAVING ANTIHYPERGLYCEMIC ACTIVITY | SHAMAN PHARMACEUTICALS, INC. (US) | 1997-08-21 | — | — | WO | disclosed |
| WO-1996010015-A1 | CRYPTOLEPINE ANALOGS WITH HYPOGLYCEMIC ACTIVITY | SHAMAN PHARMACEUTICALS, INC. (US) | 1996-04-04 | — | — | WO | disclosed |
| JP-H07179411-A | CRYSTAL OF BENZOIC ACID DERIVATIVE AND POLYVALENT METAL SALT OF THE BENZOIC ACID DERIVATIVE | MITSUI TOATSU CHEM INC | 1995-07-18 | — | — | JP | disclosed |
| EP-0376166-A1 | Condensed quinoline system compound and process of preparation thereof | MECT CORPORATION (JP) | 1990-07-04 | — | — | EP | disclosed |
| EP-0364493-A1 | RENIN INHIBITING PEPTIDES WITH NONPEPTIDE LINKAGES | THE UPJOHN COMPANY (US) | 1990-04-25 | — | — | EP | disclosed |
| WO-1989001488-A1 | RENIN INHIBITING PEPTIDES WITH NONPEPTIDE LINKAGES | THE UPJOHN COMPANY (US) | 1989-02-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11691983-B2 | Specifically substituted benzofuro- and benzothienoquinolines for organic light emitting diodes | KCNQ2, KCNQ1, KCNQ4 | HCAR2 2204/4885MAPK10 3518/4885TSHR 2470/4885 |
| US-20190161497-A1 | SPECIFICALLY SUBSTITUTED BENZOFURO- AND BENZOTHIENOQUINOLINES FOR ORGANIC LIGHT EMITTING DIODES | KCNQ2, KCNQ1, KCNQ4 | HCAR2 2204/4885MAPK10 3518/4885TSHR 2470/4885 |
| US-20110065676-A1 | COMBINATION THERAPIES COMPRISING PAR1 ANTAGONISTS WITH NAR AGONISTS | F2R, F2RL1, F2RL3 | HCAR2 97/4885MAPK10 2100/4885TSHR 1925/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.